Abstract
Talabostat mesilate is an orally active, specific inhibitor of dipeptidyl peptidases, including tumor-associated fibroblast activation protein. However, by an independent mechanism, talabostat also stimulates the upregulation of cytokines and chemokines to engender a tumor-specific host immune response, thus giving it a unique dual mechanism of action. In clinical trials, talabostat has demonstrated significant activity, including achieving complete responses in patients with non-small-cell lung cancer and malignant melanoma.
MeSH terms
-
Animals
-
Antineoplastic Agents / chemistry*
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use*
-
Boronic Acids / pharmacology
-
Boronic Acids / therapeutic use*
-
Carcinoma, Non-Small-Cell Lung / drug therapy
-
Carcinoma, Non-Small-Cell Lung / enzymology
-
Carcinoma, Non-Small-Cell Lung / immunology
-
Dipeptides
-
Dipeptidyl-Peptidases and Tripeptidyl-Peptidases / antagonists & inhibitors*
-
Drugs, Investigational / chemistry*
-
Drugs, Investigational / pharmacology
-
Drugs, Investigational / therapeutic use*
-
Enzyme Inhibitors / pharmacology
-
Enzyme Inhibitors / therapeutic use*
-
Humans
-
Melanoma / drug therapy
-
Melanoma / enzymology
-
Melanoma / immunology
-
Pyrrolidines / pharmacology
-
Pyrrolidines / therapeutic use*
Substances
-
Antineoplastic Agents
-
Boronic Acids
-
Dipeptides
-
Drugs, Investigational
-
Enzyme Inhibitors
-
Pyrrolidines
-
Dipeptidyl-Peptidases and Tripeptidyl-Peptidases
-
talabostat